Category: Alex Therapeutics

  • Study of Vicore’s DTx for anxiety in IPF patients gets underway

    Sweden’s Vicore Pharma has started a clinical trial of a digital therapeutic (DTx) intended to relieve anxiety in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and progressive respiratory disease with no curative treatment. The COMPANION study will test a cognitive behavioural therapy-based DTx called Almee (formerly VP04) – developed in partnership with digital health […]

  • Vicore signs deal with Alex to develop digital therapeutic to support IPF patients

    Rare disease specialist Vicore Pharma has signed an agreement with Alex Therapeutics to test a digital therapeutic designed to provide cognitive behavioural therapy support to patients with the lung scarring disease idiopathic pulmonary fibrosis (IPF). The agreement allows for a clinical development programme for Vicore’s digital therapeutic (DTx) VP04. Vicore will own all rights to […]